Amidst the ongoing tussle to make cannabis use legal, the recent M&A deals in this industry have attracted many large institutional investors to the marijuana sector.
Uruguay was the first country to approve marijuana in 2013, followed by Canada this year. Weed is permitted in nine US states for recreational use and in 30 states for therapeutic purposes. Oklahoma, which approved marijuana usage in the June end, was the 30th US state in this list.
A week ago, Corona beer maker Constellation Brands (STZ) upped its stake in the world’s largest medical marijuana company Canopy Growth (NYSE: CGC) by acquiring 104.5 million shares of the Canada-based company for C$48.6 per share. The winemaker had already invested $191 million in Canopy last October. In the last one week, Canopy has skyrocketed over 50% and on Tuesday the stock grew 3.01% to $38.67.
You may also like: Constellation increases stake in Canopy Growth
Trading in cannabis stocks was higher on Tuesday as these companies announced supply agreements with retail operators ahead of the launch of the cannabis recreational market in October 2018. Canadian-based pot company Cronos Group (Nasdaq: CRON) that got listed on Nasdaq in February this year, announced its initial supply agreements for retail distribution across Canada. Shares of Cronos Group jumped 13.25% to $8.29 in Nasdaq when the market closed yesterday.
Another Canadian marijuana company Tilray (Nasdaq: TLRY), which was listed in the US in July, surged 11.25% to $39.94 at the end of Tuesday’s trading session. This was helped by the Ontario Cannabis Store’s announcement of supply agreements with 26 authorized cannabis manufacturers, including Tilray.
A report released by Arcview Market Research/BDS Analytics in June 2018 states that the US legal cannabis market is estimated to reach $11 billion in consumer spending in 2018 and $23.4 billion in 2022. The report adds that the global spending is expected to hit $32 billion by 2022. Also, the roll-out of international legalization is touted to reduce the US share from 90% in 2017 to 73% in 2022.
In its February 2018 report, Arcview Market Research/BDS Analytics stated that the global spending on legal cannabis is estimated to reach $57 billion by 2027 with North America accounting for $47.3 billion. However, headwinds like volatility in the marijuana industry and inconsistent regulations might curtail the expansion opportunities for marijuana producers.
Most Popular
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported worldwide net revenues of $13.3 billion for the
Colgate-Palmolive (CL) Q1 2025 Earnings: Key financials and quarterly highlights
Colgate-Palmolive Company (NYSE: CL) reported its first quarter 2025 earnings results today. Net sales decreased 3.1% year-over-year to $4.9 billion. Organic sales growth was 1.4%. Net income attributable to Colgate-Palmolive Company rose
Meta Platforms (META) set to report Q1 earnings. Here’s what to expect
After integrating artificial intelligence into its products, Meta Platforms, Inc. (NASDAQ: META) is investing heavily in the metaverse project. Yet, the tech giant has maintained healthy cash flows and consistently
Comments
Comments are closed.